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Abstract
Background:  The adoptive transfer of autologous tumor reactive lymphocytes can mediate
significant tumor regression in some patients with refractory metastatic cancer. However, a
significant obstacle for this promising therapy has been the availability of highly efficient methods to
rapidly isolate and expand a variety of potentially rare tumor reactive lymphocytes from the natural
repertoire of cancer patients.
Methods:  We developed a novel in vitro T cell cloning methodology using high throughput
quantitative RT-PCR (qPCR assay) as a rapid functional screen to detect and facilitate the limiting
dilution cloning of a variety of low frequency T cells from bulk PBMC. In preclinical studies, this
strategy was applied to the isolation and expansion of gp100 specific CD8+ T cell clones from the
peripheral blood of melanoma patients.
Results: In optimization studies, the qPCR assay could detect the reactivity of 1 antigen specific T
cell in 100,000 background cells. When applied to short term sensitized PBMC microcultures, this
assay could detect T cell reactivity against a variety of known melanoma tumor epitopes. This
screening was combined with early limiting dilution cloning to rapidly isolate gp100154–162 reactive
CD8+ T cell clones. These clones were highly avid against peptide pulsed targets and melanoma
tumor lines. They had an effector memory phenotype and showed significant proliferative capacity
to reach cell numbers appropriate for adoptive transfer trials (~1010 cells).
Conclusion: This report describes a novel high efficiency strategy to clone tumor reactive T cells
from peripheral blood for use in adoptive immunotherapy.
Background
Adoptive immunotherapy with autologous tumor infil-
trating lymphocytes (TIL) in conjunction with a lym-
phodepleting conditioning regimen can mediate
significant tumor regression in ~50% of patients with
refractory metastatic melanoma [1,2]. However, not all
patients with melanoma are eligible for this type of
immunotherapy either because resectable tumor is not
available, the lymphocytes from the specimen do not
expand sufficiently, or the lymphocytes that do proliferate
do not exhibit sufficient tumor specific reactivity. When
reactive polyclonal TIL are generated, the composition is
largely unknown and can vary significantly between
patients. Thus, it has been difficult from these pilot clini-
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cal studies to define an "optimal" population of lym-
phocytes suitable to consistently mediate tumor
regression in melanoma patients. We hypothesized that
an iterative strategy of isolation, transfer, and clinical eval-
uation of a series of autologous tumor reactive lym-
phocyte clones would help to define the antigenic targets
and lymphocyte characteristics associated with therapeu-
tic efficacy for future adoptive immunotherapy efforts.
Further, we hypothesized that isolation of these lym-
phocytes from peripheral blood (PBL) would have several
advantages. From a practical perspective, procuring tumor
reactive lymphocytes from a blood draw or leukapheresis
would avoid the need for surgery and the potential for
post-operative complications and delays. The broad reper-
toire of PBL might allow for the isolation of unique pop-
ulations of tumor reactive lymphocytes that are not
commonly found in TIL. Finally, the use of PBL may serve
as a generalized strategy to isolate tumor reactive lym-
phocytes from patients with diverse histologies and, thus,
expand the therapeutic relevance of this approach.
A significant obstacle to this clinical strategy has been the
availability of highly efficient in vitro methods to rapidly
isolate and expand tumor reactive T cell clones from the
peripheral repertoire. Many attractive tumor antigens are
derived from normal self proteins and conventional views
of immunologic tolerance suggest that T cells reactive
against these self antigens are rare in the natural periph-
eral repertoire and are predominantly of low functional
avidity, incapable of recognizing tumor cells. Not surpris-
ingly, prior clinical trials isolating specific populations of
melanoma reactive T cells from PBL have typically relied
on repetitive in vitro antigen stimulation over extended
culture periods [3-6] and/or the need for peptide/MHC
multimer sorting to help enrich for low frequency T cells
[7]. Further, these studies [4-6] have almost exclusively
focused on the isolation of MART reactive CD8+ T cells
which can naturally exist at high frequencies in the
peripheral repertoire of both melanoma patients and
healthy individuals [8]. The adoptive transfer of lower fre-
quency CD8+ T cells from peripheral blood that recognize
other melanoma antigens, such as gp100, has been stud-
ied in few patients [6] or has required heteroclitic peptide
immunization of the host to increase the precursor fre-
quency prior to isolation [9-11].
To overcome the significant challenge of efficiently clon-
ing a variety of potentially rare tumor reactive lym-
phocytes from the natural peripheral blood repertoire of
cancer patients, we developed a novel in vitro methodol-
ogy using quantitative RT-PCR (qPCR) as a high through-
put functional screen to identify low frequency T cell
clones for rapid isolation. In this report we describe the
development of this methodology and an example of its
application in the isolation and expansion of low fre-
quency gp100154–162 reactive CD8+ T cell clones from
peripheral blood for use in adoptive immunotherapy clin-
ical trials.
Methods
Media and cell culture
Human cultured cell lines included T2 cells (HLA-A2+
peptide transporter-associated protein deficient T-B
hybrid), melanoma tumor lines (526 mel, 624 mel, 888
mel), and a hepatoma cell line (Hep 3B). All of these cell
lines were routinely cultured in complete medium (CM)
consisting of RPMI 1640 supplemented with 10% heat-
inactivated fetal bovine serum, 2 mM L-glutamine (Invit-
rogen, Carlsbad, CA), 50 units/mL penicillin (Invitrogen),
50  μg/mL streptomycin (Invitrogen), 50 μg/mL gen-
tamicin (Invitrogen), 10 mM Hepes (Invitrogen), and 250
ng/mL Amphotericin B (Invitrogen). Human lym-
phocytes were cultured in CM with 10% heat-inactivated
human AB serum (Gemini Bio-Products, Woodland, CA).
The CD8+ T cell clone, C6E4, recognizes the gp100154–162
epitope and was generated by limiting dilution from the
peripheral blood of a patient with metastatic melanoma.
Patient PBMC
PBMCs used in this study were obtained by leukapheresis
from HLA-A2+ metastatic melanoma patients evaluated
on IRB approved protocols at the Surgery Branch,
National Cancer Institute (NCI, National Institutes of
Health, Bethesda, MD).
Peptides
Synthetic peptides were made using a solid phase method
on a peptide synthesizer (Gilson) at the Surgery Branch
(NCI). The purity of each peptide was confirmed by mass
spectrometry and each was resuspended to 1 mg/ml for in
vitro use. The sequences of the peptides used in this study
are as follows: gp100209–217  (ITDQVPFSV), gp100154–
162(KTWGQYWQV), MART-127–35  (AAGIGILTV),
HIVpol476–484  (ILKEPVHGV), and FLU M158–66
(GILGFVFTL).
In vitro sensitization of PBMC
PBMC from HLA-A2+ melanoma patients underwent in
vitro sensitization for a total of either 6 or 10 days as fol-
lows: On day 0, cryopreserved PBMC's were thawed,
washed twice with CM, and plated in a 96-well plate (3 ×
105  cells/well; 0.2 mL/well). Plates were incubated at
37°C in 5%CO2 overnight to recover from the thaw. On
day 1, the sensitizing peptide was added to the PBMC cul-
ture plate at a final concentration of 1 μg/ml. On day 2, 90
IU/ml recombinant interleukin 2 (IL-2; Chiron Co., Emer-
yville, CA) was added to the cultures. On day 6, the sensi-
tized cultures were assayed for peptide reactivity by either
the qPCR assay or ELISA based cytokine release assay.
Alternatively, for some experiments, sensitization was per-Journal of Translational Medicine 2008, 6:60 http://www.translational-medicine.com/content/6/1/60
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formed for a total 10 days. This procedure was identical to
the 6 day sensitization except that an additional peptide
exposure was performed on day 6, IL-2 (90 IU/ml) was
added on day 7, and the cultures assayed for reactivity on
day 10.
High throughput real-time interferon-γ qPCR assay
On the day of assay (day 6 or 10), T2 cells were pulsed sep-
arately with the relevant sensitizing peptide and an irrele-
vant peptide at 1 μg/ml in medium for ~2 hrs at 37°C,
followed by washing to remove unbound peptide. From
each bulk PBMC culture to be assayed, two equal aliquots
of cells (each ~50 μl) were removed and incubated in par-
allel with 4 × 104 T2 cells (pulsed with either relevant or
irrelevant peptides) in a 0.2-ml volume in individual
wells of a 96 well U-bottom tissue culture plate. After 3
hours of incubation, the 96 well plate was spun (900
RPM, 5 minutes), the supernatant completely discarded,
and the cell pellet placed in RLT lysis buffer (Qiagen,
Valencia, CA). RNA isolation was performed in a 96 well
format using the RNeasy 96 BioRobot 8000 kit (Qiagen).
Total RNA for each sample was transcribed into comple-
mentary DNA (cDNA) using TaqMan Reverse Transcrip-
tion Reagants (Applied Biosystems, Foster City, CA).
Quantitative real-time PCR was performed to determine
the copy number for interferon-γ (IFN-γ) mRNA in each
sample, as described previously [12,13] using the ABI
7500 Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA). The IFN-γ mRNA levels in response to the
relevant peptide was divided by the IFN-γ mRNA levels
induced by the irrelevant HIVpol peptide to define a stim-
ulation index (SI) for each parental PBMC culture: SI =
IFN-γ (peptide x)/IFN-γ (HIVpol). A PBMC sample with a
SI > 2 was considered as having specific peptide reactivity.
All samples analyzed had CT values less than 35 cycles to
ensure the quality of the PBMC samples in the assay.
ELISA based cytokine release assay
PBMC and derived lymphocyte cultures were tested for
antigen specific reactivity in a cytokine release assay using
commercially available IFN-γ ELISA kits (Endogen). T2
cells were pulsed with peptide (1 μg/ml or as described in
the figures) in medium for ~2 hrs at 37°C, followed by
washing before initiation of co-cultures. For these assays,
105  responder cells (PBL or cloned T cells) and
105stimulator cells (T2 cells or tumor lines) were co-incu-
bated in a 0.2-ml volume in individual wells of a 96-well
plate. Supernatants were harvested from duplicate wells
after 20–24 hours and IFN-γ secretion was measured in
culture supernatants diluted as to be in the linear range of
the assay. All data is presented as a mean of duplicate sam-
ples. Cultures with IFN-γ production greater than 100 pg/
ml and twice background were considered as having spe-
cific antigen reactivity.
Cloning and expansion of antigen specific T cells
The individual cultures that exhibited the highest specific
peptide reactivity by the qPCR assay were selected for lim-
iting dilution cloning. Briefly, PBMC from a reactive cul-
ture were plated between 1 and 5 cells/well in 96-well U-
bottom plates in 0.2 ml CM containing 30 ng/ml ortho-
anti-CD3 (Ortho-Biotech, Raritan, NJ) and 300 IU/ml IL-
2 with 5 × 104 allogeneic irradiated (4000 rad) PBMCs/
well derived from at least 3 different donors. On day 5 and
every 3–4 days thereafter, half of the media in each well
was replaced with fresh media containing IL-2. Approxi-
mately 2 weeks after culture initiation, wells in which cell
growth was visibly apparent were screened in a microcyto-
toxicity assay to identify clones with cytolytic activity
against peptide pulsed T2 cells. Further characterization of
clone function was performed using IFN-γ secretion (as
described above) in response to limiting concentrations
of peptide pulsed onto T2 cells and antigen positive tumor
lines. Selected clones were rapidly expanded with 30 ng/
ml ortho-anti-CD3 and 5 × 106  irradiated allogeneic
PBMCs in upright 25-cm2 flasks as described previously10.
Additional rapid expansions were performed to deter-
mine proliferative capacity of clones. Expanded clones
were re-evaluated for peptide and tumor recognition and
cell surface phenotype by FACS.
Tetramers, mAbs, and flow cytometric 
immunofluorescence analysis
Allophycocyanin-labeled gp100209–217 (ITDQVPFSV) pep-
tide/HLA-A*0201 tetramer complexes were obtained
from Immunotech, Beckman Coulter. Phycoerythrin-con-
jugated gp100154–162  (KTWGQYWQV) peptide/HLA-
A*0201 tetramer complexes were obtained from the
National Institutes of Health Tetramer Facility. FITC-con-
jugated anti-CD8, CD25, CD27, CD28, CD45RO,
CD45RA, CD62L (L-selectin) monoclonal antibodies
were obtained from BD Biosciences. Immunofluores-
cence, analyzed as the relative log fluorescence of live
cells, was measured using a FACScan flow cytometer (BD
Biosciences). A combination of forward angle light scatter
and propidium iodide staining was used to gate out dead
cells. Approximately 1 × 105 cells were analyzed. Cells
were stained in a FACS buffer made of PBS (BioWhittaker)
and 0.5% BSA.
Results
Development of a sensitive qPCR functional assay for the 
detection of low frequency antigen specific T cells in 
peripheral blood
Sensitive detection of rare antigen specific T cells in bulk
heterogeneous populations is essential to their rapid and
efficient isolation. We originally described the measure-
ment of antigen induced interferon-γ mRNA by qPCR as a
highly sensitive functional assay that could detect the
reactivity of low frequency antigen specific CD8+ T cellsJournal of Translational Medicine 2008, 6:60 http://www.translational-medicine.com/content/6/1/60
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directly from peripheral blood samples [12,13]. We
sought to apply this qPCR assay to the semi-automated
high throughput functional screening of 96 well plate
microcultures containing approximately 150,000 bulk
PBMCs and compare these results to our conventional T
cell screening evaluation using interferon-γ ELISA of the
culture supernatant. In order to determine the sensitivity
for both assays in this microwell screening format, we per-
formed a spiking experiment where varying absolute
numbers of the C6E4 gp100154–162 reactive CD8+ T cell
clone were spiked into 150,000 nonreactive autologous
bulk PBMCs (Figure 1). No exogenous cytokines were
added and culturing of the cells was not performed. The
spiked PBMC were immediately tested for their ability to
recognize T2 cells pulsed with the relevant gp100154–162
peptide (1 uM) and an irrelevant HIVpol peptide (1 uM).
Cellular interferon-γ mRNA production was measured by
qPCR at 3 hours after the co-incubation and supernatant
interferon-γ protein production was measured at 24 hours
by ELISA. Stimulation indexes (SI) for both assays were
determined by dividing the reactivity against the relevant
peptide by the reactivity against the irrelevant peptide (SI
= gp100154–162/HIVpol). In the eight replicate wells with-
out spiked C6E4 clone (PBMC alone), neither assay dem-
onstrated significant reactivity (gp100154–162/HIVpol SI <
2). The qPCR assay did identify T cell reactivity in all rep-
licate wells containing between 3000 and 150 spiked
clones (Figure 1A). In at least 2 of the 8 replicate wells, the
qPCR assay could detect reactivity at every dilution down
to 1.5 cells spiked into 150,000 PBMC. In contrast, the
detection limit for interferon-γ protein ELISA was reached
in samples with 300 cells spiked into 150,000 PBMC (Fig-
ure 1B). We concluded that the qPCR functional assay had
a significantly higher sensitivity compared with standard
ELISA and it could detect the antigen induced cytokine
response of approximately a single CD8+ T cell at precur-
sor frequency of ~1:100,000 in a 96 microwell format.
qPCR functional screening rapidly identifies melanoma 
antigen specific T cells in short term sensitized peripheral 
blood cultures
We next applied the qPCR assay to the screening of PBMC
for natural CD8+ T cell reactivity against known epitopes
from the melanocytic differentiation antigens, gp100 and
MART. Peripheral blood leukapheresis samples were
obtained from 17 HLA-A2+ metastatic melanoma patients
Comparison between qPCR and ELISA based assays in the functional detection of antigen specific T cells Figure 1
Comparison between qPCR and ELISA based assays in the functional detection of antigen specific T cells. 
Between 1.5 and 3000 gp100154–162 reactive CD8+ T cell clones (C6E4) were spiked into 150,000 nonreactive autologous 
PBMC in individual microwells (n = 8) of a 96 well plate and immediately tested for T cell recognition of T2 cells pulsed with 
gp100154–162 peptide (1 μM) and HIVpol peptide (1 μM). (A.) qPCR Assay. Cellular IFN-γ mRNA production was measured by 
qPCR at 3 hours and reported as a stimulation index (SI). SI = IFN-γ mRNA (gp100154–162)/IFN-γ mRNA (HIVpol). Reactive 
wells (SI > 2) could be identified at every dilution down to 1.5 cells spiked into 150,000 PBMC. (B.) ELISA Assay. Supernatant 
IFN-γ protein production was measured at 24 hours by standard ELISA. SI = IFN-γ protein (gp100154–162)/IFN-γ protein 
(HIVpol). Reactive wells (SI > 2) could be identified at dilutions down to 300 cells spiked into 150,000 PBMC. (O) represents 
the SI for each microwell. Shaded area represents range of non-specific reactivity (SI ≤ 2).Journal of Translational Medicine 2008, 6:60 http://www.translational-medicine.com/content/6/1/60
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who had not previously undergone antigen specific
immunotherapy (i.e. vaccine or cell based transfer ther-
apy). Bulk PBMC from each patient were plated in repli-
cate microwells (n = 24) containing ~300,000 cells each
and individually sensitized for 6 days with 1 uM of
FLUM1, MART27–35, gp100209–217, gp100154–162, or no
peptide (DMSO) in the presence of IL-2 (90 IU/ml). On
day 6, a sample from every microculture (~100,000 cells)
was screened using the qPCR assay for recognition of the
respective sensitizing peptide versus the irrelevant HIVpol
peptide pulsed onto T2 cells (Figure 2). The interferon-γ
gene expression was normalized as a SI (peptide x/
HIVpol). The bulk cells cultured in IL-2 with no sensitizing
peptide (DMSO alone) were used to define the level of
nonspecific background reactivity for each patient (Figure
2E). The median DMSO/HIVpol SI for all patients was 1.0
(S.D. ± 0.3) with individual wells ranging from 0.5 to 2.0.
By using a cutoff SI value of 2.0, we identified significant
microculture reactivity against the FLUM1 peptide in all
17 patients (Figure 2A), which served as an internal posi-
tive control for the sensitization procedure. Variability in
the median FLUM1/HIVpol SI of the replicate wells was
observed across patients (median range: 3.0 to 376), con-
sistent with varying degrees of natural peripheral blood
CD8+ T cell reactivity against the FLU epitope. Further,
despite uniform culture conditions, marked well to well
variability within the culture replicates was noted for sev-
eral patients. Among the cultures sensitized for 6 days
with the melanoma antigen epitopes, variable immune
reactivity was similarly observed. qPCR analysis of the cul-
tures sensitized with MART27–35 (Figure 2B) revealed three
patients (Patients 1, 4, and 6) with median MART/HIV SI
well reactivity above 2. However, in 12 patients (70.5%),
the qPCR assay identified at least one individual microc-
ulture replicate which met criteria for significant MART
peptide reactivity. Similarly, among the gp100209–217 sen-
sitized cultures, only 4 patients (Patients 1, 2, 6, and 11)
had median culture reactivity > 2, but 16 of 17 (94%)
patients were found to have individual wells with peptide
reactivity above background (Figure 2C). Among the 8
patients sensitized with the gp100154–162  peptide, one
patient (patient 7) had median culture reactivity > 2, but
6 patients (75%) had individual wells with peptide reac-
tivity (Figure 2D). In sum, CD8+ T cell reactivity against at
least one of the melanoma epitopes was identified in 16
of the 17 patients (94%). We concluded that the qPCR
assay could be used as a highly efficient and rapid screen
to detect the reactivity of a variety of melanoma specific T
cells in short term sensitized PBMC microcultures.
To determine whether the immune reactivity identified at
day 6 by the qPCR assay could also be detected by ELISA,
gp100209–217 sensitized microcultures from patients 1 and
3 were evaluated using both assays with an equivalent
number of sampled PBMC (~100,000 cells) from each of
the replicate wells (Figure 3A and 3B). ELISA evaluation
did not identify any wells from either patient with reactiv-
ity above background. In contrast the qPCR assay per-
formed on the same wells demonstrated multiple cultures
with detectable peptide reactivity. To confirm that the
qPCR reactivity in these early cultures independently cor-
related with the presence of gp100209–217 specific T cells,
the microcultures with the highest and lowest SIs were
rapidly expanded with anti-CD3, allogenic feeder cells,
and IL-2 over 1 week and evaluated for the presence and
activity of gp100209–217 reactive CD8+ T cells (Figure 3A
and 3B). By day 14, the expanded cultures from the wells
with the high SI (Patient 1, SI = 11.1 and 12.4; Patient 3,
SI = 3.3) demonstrated a distinct population of antigen
specific CD8+ T cells when stained with the gp100209–217
tetramer (3–5% of CD8+ cells). When samples of these
expanded cultures were tested for functional recognition
of T2 cells pulsed with the gp100209–217 peptide, they
released significant amounts of interferon-γ protein that
could now easily be detected by ELISA. In contrast, the
expanded cultures from the low SI wells (Patient 1, SI =
1.1; Patient 3, SI = 0.8) had neither discernable tetramer
positive cells nor functional activity against peptide
pulsed targets. We concluded that the qPCR assay could
be used at an early time point to stratify the epitope reac-
tivity of short term sensitized PBMC microcultures to pro-
spectively identify selected wells enriched for functionally
active antigen specific T cells and to identify wells with no
evidence of reactivity.
A novel strategy for high throughput isolation of low 
frequency melanoma specific T cell clones from peripheral 
blood
We next sought to incorporate the qPCR functional assay
into a novel strategy for high throughput isolation of low
frequency antigen specific CD8+ T cell clones from bulk
PBMC for use in adoptive immunotherapy trials. We ini-
tially aimed to isolate CD8+ T cell clones reactive against
the gp100154–162 epitope given their extremely low natural
frequency in peripheral blood, the difficulty in prospec-
tively isolating these T cells, and the limited published
reports of T cell clones reactive against this epitope [7].
The basic isolation strategy is summarized in Figure 4.
PBMC from an HLA-A2+ patient with metastatic
melanoma are used to establish 96 independent microc-
ultures which are sensitized for 10 days with 1 uM of
gp100154–162 in the presence of IL-2 (90 IU/ml). On day
10, a sample from every microculture is screened using the
qPCR assay for specific recognition of the gp100154–162
peptide versus the HIVpol peptide. The SI reactivities for
the 96 wells are stratified by their magnitude and the most
reactive microcultures are selected for the next step, limit-
ing dilution cloning. After approximately 2 weeks, growth
positive wells are screened for their ability to lyse peptide
pulsed T2 cells and melanoma tumor lines. Selected T cellJournal of Translational Medicine 2008, 6:60 http://www.translational-medicine.com/content/6/1/60
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qPCR functional screening rapidly detects the reactivity of melanoma antigen specific T cells in short term sensitized peripheral  blood cultures Figure 2
qPCR functional screening rapidly detects the reactivity of melanoma antigen specific T cells in short term 
sensitized peripheral blood cultures. PBMC from 17 HLA-A2+ melanoma patients were plated in replicate microwells (n 
= 24) containing ~300,000 cells and individually sensitized for 6 days with either 1 μM of (A.) FLUM1, (B.) MART27–35, (C.) 
gp100209–217, (D.) gp100154–162, or (E.) no peptide (DMSO) in the presence of IL-2 (90 IU/ml). On day 6, a sample from every 
microculture (~100,000 cells) was screened using the qPCR assay for T cell recognition of the respective sensitizing peptide 
versus the HIVpol peptide pulsed onto T2 cells. Stimulation Index (SI) = IFN-γ mRNA (peptide x)/IFN-γ mRNA (HIVpol). (O) 
represents the SI for each microwell. Bar is median SI value. (*), not done. Shaded area represents range of non-specific reac-
tivity (SI = 0.5–2.0).Journal of Translational Medicine 2008, 6:60 http://www.translational-medicine.com/content/6/1/60
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clones are then expanded in the final step for further anal-
ysis and potential use in adoptive immunotherapy trials.
This strategy was applied to PBMC from four melanoma
patients (patients 2, 5, 6, and 7) (Figure 5). A sample of
the bulk PBMC from each patient, prior to any in vitro
manipulation underwent staining with the gp100154–162
tetramer to determine natural precursor frequency. None
of the patients demonstrated a significant population of
tetramer positive CD8+ T cells by FACS on day 0 (Figure
5A). After 10 days of sensitization, the 96 independent
microcultures for each patient were screened for peptide
reactivity using the qPCR assay (Figure 5B). The stratified
results for Patients 2, 5, and 6 demonstrated that only 7%,
12%, and 8% of the wells had a SI ≥ 2, respectively; 1%,
3%, and 1% of the wells had a SI ≥ 10, respectively; and
the remaining wells had no detectable peptide reactivity
(SI < 2). In contrast, for Patient 7, 92% of the wells had a
SI ≥ 2 and 60% of the wells had a SI ≥ 10. The highest reac-
tive microcultures from patients 2, 5, 6, and 7 (qPCR SI =
45, 635, 23, and 78, respectively) were selected for limit-
ing dilution cloning. The frequencies of growth positive
clones with lytic ability against peptide pulsed targets
were 0.2%, 28%, 0.1%, and 2.3% for the respective
patients, which directly correlated with the qPCR SI (r2 =
0.99, p < 0.0001). These selected clones were expanded
and underwent FACS analysis between days 25 and 34 to
reveal highly enriched populations (99%) of gp100154–162
tetramer positive CD8+ T cells (Figure 5C). Further, the
derived populations were confirmed to be clonal by the
sequencing of a single T cell receptor Vα and Vβ chain for
each patient (Table 1). The functional avidity of these iso-
lated T cell clones was high, as measured by their ability
The magnitude of qPCR reactivity prospectively identifies selected wells enriched for functionally active antigen specific T cells Figure 3 (see previous page)
The magnitude of qPCR reactivity prospectively identifies selected wells enriched for functionally active anti-
gen specific T cells. Day 6 gp100209–217 sensitized microcultures (n = 24) from patients 1 (A.) and 3 (B.) were evaluated in 
parallel using qPCR and ELISA assays. Significant well reactivity was detected with the qPCR assay, but not with ELISA. Microc-
ultures with the highest and lowest qPCR SIs were selected (see arrow) for rapid expansion. On day 14, the phenotype of the 
expanded cultures was assessed by staining with gp100209–217 peptide/HLA-A*0201 tetramers and anti-CD8 antibody and anal-
ysis by flow cytometric analysis. Dot plots are shown for propidium iodide–negative gated cells. Values in FACS dot plots cor-
respond to the percentage of total CD8+ T cells that are tetramer-positive calculated as the number of CD8+ tetramer+ cells 
divided by the total number of CD8+ T cells minus the CD8- tetramer+ background × 100. Functional reactivity of the 
expanded cultures was assessed by co-culture with peptide pulsed T2 cells and supernatant analysis by standard ELISA for IFN-
γ protein at 24 hrs. ELISA data represents the average of replicate co-culture wells. (O) represents the SI for each microwell. 
Shaded area represents range of non-specific reactivity (SI = 0.5–2.0). (*), not detectable.
Table 1: TCR α/β Complementarity Determining Region Residues Identified from gp100154–162 specific CD8+ T cell clones
α-CDR1 α-CDR2 α-CDR3
TRAV
Patient 2 12.1 N S A S Q S V Y S S G V V N M N S N Y Q L I
Patient 5 8.1 Y G G T V N Y F S G D P L A V N G D D K I I
Patient 6 5 D S S S T Y I F S N M D A E M A N S G Y A L N
Patient 7 5 D S S S T Y I F S N M D A E N P E G N D M R
β-CDR1 β-CDR2 β-CDR3
TRBV
Patient 2 15 L N H N V Y Y D K D F A T S Q E A S F T D T Q Y
Patient 5 7.6 S G H V S F N Y E A Q A S S L G G G Q D T Q Y
Patient 6 12.3 S G H N S F N N N V P A S S P G G G E Q F
Patient 7 11.2 S G H A T F Q N N G V A S S P G G G G E Q FJournal of Translational Medicine 2008, 6:60 http://www.translational-medicine.com/content/6/1/60
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to recognize 10-10  to 10-11  M of gp100154–162  peptide
pulsed onto T2 cells and HLA A2+/gp100+ melanoma
tumor lines in vitro (Table 2). The phenotype of these cells
was assessed by cell surface FACS for CD27, CD28,
CD45RO, CD45RA, CD62L, and CD25 (Figure 6). The
gp100154–162 tetramer positive cells from patients 2, 5, and
7 all were uniformly CD45RO+ and CD62L-, consistent
with an effector memory phenotype. However, unlike typ-
ical antigen experienced T cells, there was persistent varia-
ble expression of CD45RA (19–96%). In addition all of
the isolated clones continued to have significant expres-
sion of the costimulatory molecule CD27 (90–99%). This
phenotype differed from the terminally differentiated TIL
derived MART27–35 specific clone, JKF6, which had no sig-
nificant expression of CD27. Since initiating these isola-
tion studies we have successfully cloned gp100154–162
CD8+ T cells in 6 of 8 patients (75%). In pilot clinical
scale expansions, these clones demonstrated between
850–1000 fold expansions in cell numbers over the initial
14 days after a single rapid expansion in flasks. A second
serial expansion of these clones resulted in an additional
400–600 fold expansion over the ensuing week. Thus, we
found that with two consecutive rapid expansions ~1010
cells could be generated for potential clinical adoptive
transfer from each starting clone isolated.
Discussion
Cancer immunotherapy by means of adoptive transfer of
antigen specific T cells has several conceptual advantages.
First, lymphocytes with high avidity against specific tumor
antigens can be selected. Next, the lymphocytes can be
activated ex-vivo to exhibit anti-tumor effector function
and expanded to large numbers for administration.
Finally, the host may be manipulated to facilitate the
function and persistence of the transferred cells. The evi-
dence that this immunotherapy approach can mediate
significant tumor regression comes from clinical studies
transferring ex vivo expanded TIL to lymphodepleted met-
astatic melanoma patients [1,2]. However, given the pol-
yclonal nature of bulk TIL, it has been difficult from these
early studies to define a putative "optimal" T cell popula-
tion that can predictably result in tumor regression. Anal-
yses of pre-clinical and clinical studies of adoptive
immunotherapy have suggested potential lymphocyte
characteristics associated with improved outcome. Murine
studies of adoptive transfer have demonstrated that high
avidity CTL possess superior in vivo anti-viral and anti-
tumor efficacy when compared to low avidity CTL
[14,15](In the pmel murine model of melanoma, adoptive
transfer of CTL with terminal effector function and pheno-
type induced by repetitive in vitro antigen and IL-2 stimu-
lation was associated with impaired in vivo anti-tumor
efficacy [16]. Thus, the adoptive transfer of less differenti-
ated antigen specific cells with an early effector memory
phenotype was advocated. Retrospective evaluation of
human trials administering melanoma reactive TIL have
suggested that longer telomere length of bulk TIL corre-
lated with in vivo persistence and tumor regression in
melanoma patients receiving cell transfer [17]. Further,
the number of CD27+/CD8+ T cells in bulk TIL was asso-
ciated with the ability of these TIL to mediate tumor
regression following adoptive transfer [18]. With respect
to lymphocyte specificity, an optimal antigenic target for
the immunotherapy of melanoma has not been clearly
established in human trials. Given the many significant
variables that might influence clinical tumor response, we
hypothesized that an iterative strategy of isolation, trans-
fer, and clinical evaluation of a series of differing autolo-
gous tumor reactive lymphocyte clones would help to
define the antigenic targets and lymphocyte characteristics
associated with therapeutic efficacy.
Table 2: Peptide and tumor reactivity of gp100154–162 specific CD8+ T cell clones *
Peptide Reactivity Tumor Reactivity
gp100154 (M) HIV (M) A2+/
gp100+
A2+/
gp100+
A2-/
gp100+
A2-/
gp100-
10-6 10-7 10-8 10-9 10-10 10-11 10-12 10-6 Mel 526 Mel 624 Mel 888 Hep 3B Media
Patient 2 
clone
7105 6606 5102 2555 187 < 10 < 10 < 10 2724 5743 < 10 < 10 < 10
Patient 5 
clone
12067 11274 5323 1210 244 < 10 < 10 < 10 5114 7425 < 10 < 10 < 10
Patient 7 
clone
33349 29191 26858 18575 687 220 < 10 < 10 3975 8434 < 10 < 10 < 10
* Specific reactivity of cloned T cells was evaluated by tumor or peptide-specific stimulation. 1e5 cloned T cells were cocultured overnight with an 
equal number of melanoma tumor cells or T2 cells pulsed with either 1 μM irrelevant HIV peptide or titered concentrations of gp100:154–162 
peptide, and assessed for IFN-g (pg/ml) production by standard ELISA
Values 100 pg/ml and twice background are bolded and underlined.Journal of Translational Medicine 2008, 6:60 http://www.translational-medicine.com/content/6/1/60
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Critical to this approach is the ability to identify, isolate
and expand a variety of self reactive T cell clones that exist
at low frequencies in the natural T cell repertoire. There-
fore, to conduct these investigations, we developed a
novel in vitro cloning methodology using quantitative RT-
PCR (qPCR) as a highly sensitive functional screen to
detect the reactivity of low frequency T cells in the periph-
eral blood of metastatic cancer patients. We determined
that the interferon-γ qPCR assay was capable of detecting
the reactivity of 1 antigen specific T cell in approximately
100,000 background cells. This sensitivity was shown to
be superior to our conventional screening using inter-
feron-γ ELISA and also compared favorably to other pub-
lished functional assays such as intracellular cytokine
FACS (1:10,000 cells), cytometric cytokine capture assays
(1:10,000 cells), and enzyme-linked immunospot (ELIS-
POT) (1:50,000 cells) [19].
The use of peptide/MHC multimers and FACS sorting has
previously been suggested as an effective means of T cell
enrichment for rapid cloning [7,20], however, this tech-
nique has generally been difficult to apply to many
tumor-specific lymphocytes because of their low precur-
sor frequency and the sensitivity limitations of FACS anal-
ysis. Furthermore, peptide/MHC complexes are capable of
measuring the presence of lymphocytes possessing the
appropriate T cell receptor but not the functional state or
the ability of these lymphocytes to respond to exposure to
tumor antigen. In our studies, the qPCR assay could detect
the functional reactivity of T cells against a variety of
known melanoma tumor epitopes (MART27–35, gp100209–
217, gp100154–162) in short term sensitized microcultures
(Figure 2). Further, the magnitude of the epitope reactivity
could be used to prospectively select individual cultures
with the greatest enrichment for functionally active anti-
gen specific T cells and, thus, eliminate the majority of
non reactive cultures after approximately one week. This
early high throughput screening step combined with
immediate limiting dilution cloning of highly selected
microcultures has allowed for the rapid and efficient iso-
lation of rare antigen specific T cell clones and has elimi-
nated the prolonged culture times typically required for
their generation. In this report, we utilized this strategy to
clone gp100154–162 reactive lymphocytes from the natural
peripheral blood repertoire of four melanoma patients, a
process that has previously been exceedingly difficult and
time consuming with conventional repetitive in vitro stim-
ulation techniques [21,22]. In addition to improved effi-
ciency of isolation, qualitative evaluation of the
lymphocytes cloned with this technique has demon-
strated several favorable characteristics. The gp100154–162
reactive clones were highly avid and could recognize
between 10-10 to 10-11 M of gp100154–162 peptide pulsed
onto T2 cells, as well as, antigen naturally processed and
presented by melanoma tumor lines. The lymphocyte cul-
tures were generated in the setting of limited peptide
exposure (~10 days) and low concentrations of IL-2 (90
IU/ml), conditions suggested as beneficial for the in vivo
efficacy of adoptively transferred T cells [16]. The
expanded clones had an effector memory phenotype with
high cell surface expression of CD27, an attribute that was
associated with tumor regression with TIL therapy [18].
Finally, these cells showed significant proliferative capac-
ity to reach cell numbers appropriate for clinical trials
(~1010  cells). For these reasons, we believe the lym-
phocytes cloned using this strategy represent a unique and
attractive population of cells for adoptive immuno-
therapy that differ from previously administered clones
generated with prolonged and repetitive in vitro stimula-
tion which have had minimal therapeutic efficacy
[5,6,10,11]. Plans are underway to clinically transfer
gp100154–162 reactive clones in conjunction with a lym-
phodepleting conditioning chemotherapy regimen to
patients with refractory melanoma.
Strategy for high throughput cloning of low frequency antigen specific T cells from peripheral blood for adoptive immuno- therapy Figure 4
Strategy for high throughput cloning of low frequency antigen specific T cells from peripheral blood for adop-
tive immunotherapy.
DAY 24
SCREENING OF CLONES
FOR FUNCTION AND 
PHENOTYPE 
DAY 0
PLATING OF PATIENT PBMC 
IN 96 MICROWELL  FORMAT 
DAY 10
HIGH THROUGHPUT  FUNCTIONAL
SCREENING OF MICROWELLS 
BY INTERFERON- PCR ASSAY
In vitro 
sensitization
Selection of
highest reactive
f
Expansion of 
selected clones for 
f with peptide/IL-2
for 10 days
microwell for limiting 
dilution cloning
adoptive transferJournal of Translational Medicine 2008, 6:60 http://www.translational-medicine.com/content/6/1/60
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Rapid cloning of gp100154–162 specific CD8+ T cells from peripheral blood Figure 5 (see previous page)
Rapid cloning of gp100154–162 specific CD8+ T cells from peripheral blood. (A.) On Day 0, PBMC from four HLA-A2+ 
melanoma patients underwent staining with gp100154–162 peptide/HLA-A*0201 tetramers and anti-CD8 APC to determine nat-
ural precursor frequency. None of the patients demonstrated a significant population of tetramer positive CD8+ T cells by 
FACS. PBMC from each patient were plated in replicate microwells (n = 96) containing ~300,000 cells and sensitized for 10 
days with 1 μM of gp100154–162 peptide in the presence of IL-2 (90 IU/ml). (B.) On day 10, a sample from every microculture 
was screened using the qPCR assay for specific recognition of the gp100154–162 peptide versus the HIVpol peptide. The wells 
with the highest SI reactivity (denoted by **) were selected for limiting dilution cloning. After approximately 2 weeks, growth 
positive wells were functional screened for their ability to lyse peptide pulsed T2 cells. Selected T cell clones were expanded 
and underwent FACS analysis (C.) between days 25 and 34 to reveal highly enriched (99%) populations of gp100154–162 
tetramer positive CD8+ T cells. Values in FACS dot plots correspond to the percentage of total CD8 + T cells that are 
tetramer-positive. (O) represents the SI for each microwell. Shaded area represents range of non-specific reactivity (SI = 0.5–
2.0).
Phenotype of gp100154–162 specific CD8+ T cell clones Figure 6
Phenotype of gp100154–162 specific CD8+ T cell clones. Peripheral blood T cell clones underwent staining with gp100154–
162 peptide/HLA-A*0201 tetramers and anti-CD8. The CD8+/tetramer+ cells were assessed for cell surface expression of 
CD27, CD28, CD45RO, CD45RA, CD62L, and CD25. Analysis was performed with multiparameter flow cytometry. Values 
on histograms represent the percentage of total CD8+ T cells that are tetramer-positive and express the indicated marker. 
JKF6 is a MART27–35 specific CD8+ T cell clone derived from TIL. ND, not done.Journal of Translational Medicine 2008, 6:60 http://www.translational-medicine.com/content/6/1/60
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An additional important aspect to our methodology is the
application of high throughput robotic automation. We
currently perform all steps involved in the screening and
isolation process with automated 96 well liquid dispens-
ing instruments which have enabled the isolation of T cell
clones in an extremely time efficient manner, a critical
requirement for metastatic cancer patients waiting for
therapy. We currently are exploring the adaptation of this
method to a 384 well automated format which would fur-
ther increase the throughput and efficiency of the cloning
procedure. Finally, the basic platform that we have
described in this report can be applied to the rapid isola-
tion of virtually any antigen specific T cell population
(CD4+ or CD8+) where the immunogenic epitope is
known. We are currently utilizing this methodology for
the isolation of other tumor and viral specific lym-
phocytes for future adoptive immunotherapy trials and
are also extrapolating this methodology to the rapid
screening and evaluation of novel epitope targets as
means of tumor antigen/epitope discovery.
Conclusion
This report describes a novel high efficiency strategy to
clone tumor reactive T cells from peripheral blood for use
in adoptive immunotherapy. We are currently utilizing
this methodology for the isolation of other tumor and
viral specific lymphocytes for future adoptive immuno-
therapy trials and are also extrapolating this methodology
to the rapid screening and evaluation of novel epitope tar-
gets as means of tumor antigen/epitope discovery.
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